No drug has yet (April 2020) been shown in a randomized double-blind placebo-controlled trial to prevent or reduce the severity of human infection with SARS-CoV-1 or SARS-CoV-2. Nevertheless, a large number of promising drug candidates have been identified on the basis of their efficacy in treatment of human infections with other RNA viruses or in diminishing cytokine storms and other pathologies due to destructive host reactions to viruses similar to SARS-CoV-1 and SARS-CoV-2. The interactions of these candidate drugs with their known viral and human protein targets are annotated.

In addition, some drugs that inhibit Cytochrome P450 (CYP) oxidoreductases have been shown to be effective in prolonging the plasma half-lives of antiviral drugs with acceptable side effects, and CYP inhibition by these drugs is annotated.

Finally, effects of any of these drugs on unrelated essential human proteins, that might limit their use in vivo are annotated.